Carlos Alban Net Worth

The estimated Net Worth of Carlos Alban is at least $80.7 Million dollars as of 16 November 2020. Mr. Alban owns over 115,830 units of Abbvie Inc stock worth over $44,897,556 and over the last 15 years he sold ABBV stock worth over $21,400,337. In addition, he makes $14,406,100 as Vice Chairman und Chief Commercial Officer at Abbvie Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Alban ABBV stock SEC Form 4 insiders trading

Carlos has made over 21 trades of the Abbvie Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 115,830 units of ABBV stock worth $4,155,980 on 16 November 2020.

The largest trade he's ever made was exercising 142,900 units of Abbvie Inc stock on 1 May 2013 worth over $3,994,055. On average, Carlos trades about 12,390 units every 82 days since 2009. As of 16 November 2020 he still owns at least 230,729 units of Abbvie Inc stock.

You can see the complete history of Mr. Alban stock trades at the bottom of the page.

Carlos Alban biography

Carlos Alban is Vice Chairman, Chief Commercial Officer of the Company. Mr. Alban is AbbVie's Executive Vice President, Commercial Operations. He served as Abbott's Senior Vice President, Proprietary Pharmaceutical Products, Global Commercial Operations from 2011 to 2012, as Senior Vice President, International Pharmaceuticals from 2009 to 2011, as Vice President, Western Europe and Canada from 2007 to 2009, and as Vice President, European Operations from 2006 to 2007. Mr. Alban joined Abbott in 1986.

What is the salary of Carlos Alban?

As the Vice Chairman und Chief Commercial Officer of Abbvie Inc, the total compensation of Carlos Alban at Abbvie Inc is $14,406,100. There are 2 executives at Abbvie Inc getting paid more, with Richard Gonzalez having the highest compensation of $21,610,600.

How old is Carlos Alban?

Carlos Alban is 56, he's been the Vice Chairman und Chief Commercial Officer of Abbvie Inc since 2018. There are 16 older and 14 younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.

What's Carlos Alban's mailing address?

Carlos's mailing address filed with the SEC is C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD, CT, 06902.

Insiders trading at Abbvie Inc

Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell und Glenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.

What does Abbvie Inc do?

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Complete history of Mr. Alban stock trades at Abbott Laboratories, Abbvie Inc und SpringWorks Therapeutics

Abbvie Inc executives and stock owners

Abbvie Inc executives and other stock owners filed with the SEC include:

• Richard Gonzalez,
  Chairman of the Board, Chief Executive Officer
• Laura Schumacher,
  Vice Chairman, External Affairs and Chief Legal Officer
• Carlos Alban,
  Vice Chairman, Chief Commercial Officer
• Michael Severino,
  President, Vice Chairman
• Robert Michael,
  Chief Financial Officer, Senior Vice President
• William Chase,
  Executive Vice President - Finance and Administration
• Richard A. Gonzalez,
  Chairman & CEO
• Dr. Michael E. Severino,
  Vice Chairman & Pres
• Laura J. Schumacher,
  Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.
• Timothy Richmond,
  Chief Human Resource Officer, Executive Vice President
• Robert A. Michael,
  Vice Chairman of Fin. & Commercial Operations and CFO
• Glenn Tilton,
  Lead Independent Director
• Robert Alpern,
  Independent Director
• Edward Rapp,
  Independent Director
• Brett Hart,
  Independent Director
• William Burnside,
  Independent Director
• Roxanne Austin,
  Independent Director
• Frederick Waddell,
  Independent Director
• Melody Meyer,
  Independent Director
• Edward Liddy,
  Independent Director
• Thomas Freyman,
  Independent Director
• Rebecca Roberts,
  Independent Director
• Brian Durkin,
  Vice President, Controller
• Jeffrey Stewart,
  Senior Vice President, U.S. Commercial Operations
• Nicholas Donoghoe,
  Senior Vice President - Enterprise Innovation
• Azita Saleki-Gerhardt,
  Executive Vice President - Operations
• Henry Gosebruch,
  Executive Vice President, Chief Strategy Officer
• Scott T. Reents,
  Sr. VP & CFO
• Jeffrey Ryan Stewart,
  Exec. VP & Chief Commercial Officer
• Henry O. Gosebruch,
  Exec. VP & Chief Strategy Officer
• Scott C. Brun M.D.,
  VP of Scientific Affairs & Head of AbbVie Ventures
• Timothy J. Richmond,
  Exec. VP & Chief HR Officer
• Elizabeth Shea,
  VP of Investor Relations
• Dr. Thomas J. Hudson,
  Sr. VP of R&D and Chief Scientific Officer
• Dr. Azita Saleki-Gerhardt,
  Exec. VP of Operations
• Thomas A. Hurwich,
  VP, Controller
• Jennifer L. Davis,
  
• Roy S Roberts,
  Director
• Laboratories Abbott,
  10% owner
• John M Leonard,
  SVP, Chief Scientific Officer
• Elaine K. Sorg,
  SVP, US COMMERCIAL OPERATIONS
• Perry C Siatis,
  EVP, GC AND SECRETARY
• Carrie C Strom,
  SVP & PRES GLOBAL ALLERG AESTH
• Thomas J Hudson,
  SVP, CSO, GLOBAL RESEARCH
• Scott T Reents,
  EVP, CHIEF FINANCIAL OFFICER
• Susan E Quaggin,
  
• Kevin K Buckbee,
  SVP, CONTROLLER
• Roopal Thakkar,
  SVP, CMO, GLOBAL THERAPEUTICS